# Phase 2 Dose-Ranging Efficacy and Safety Trial of SCH 900271 in Participants With Primary Hypercholesterolemia or Mixed Hyperlipidemia (P05675)

> **NCT00941603** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 619 (actual)

## Conditions studied

- Primary Hypercholesterolemia
- Mixed Hyperlipidemia

## Interventions

- **DRUG:** SCH 900271 15mg
- **DRUG:** SCH 900271
- **DRUG:** SCH 900271
- **DRUG:** SCH 900271
- **DRUG:** SCH 900271
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00941603
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06-29
- **Primary completion:** 2010-02-22
- **Final completion:** 2010-02-22
- **Target enrollment:** 619 (ACTUAL)
- **Last updated:** 2018-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00941603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00941603, "Phase 2 Dose-Ranging Efficacy and Safety Trial of SCH 900271 in Participants With Primary Hypercholesterolemia or Mixed Hyperlipidemia (P05675)". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT00941603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*